- AstraZeneca's (AZN +2.3%) Lesinurad treatment for gout met the primary goal of a Phase III study, although it caused a number of side effects, some of which were serious.
- The study tested Lesinurad for use in the small number of patients who are unable to take rival therapies allopurinol and febuxostat.
- The side effects included increased levels of serum creatinine, which are an important indicator of renal health.
- AstraZeneca is now waiting for the outcomes of three other Phase III trials, which are testing Lesinurad in combination with other drugs. (PR)
AstraZeneca gout drug hits Phase III goal, but safety an issue
Dec 13 2013, 07:04 ET